Fibrinolysis, inflammation, and regulation of the plasminogen activating system

Journal of Thrombosis and Haemostasis

Volumn 5, Issue SUPPL. 1, 2007, Pages 132-142

  Medcalf, Robert L ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Fibrinolysis; Gene regulation; Inflammation; MRNA stability; Transcription

Indexed keywords

CYTOKINE; PLASMINOGEN; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PROTEINASE; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR; UROKINASE; UROKINASE RECEPTOR;

3' UNTRANSLATED REGION; DIABETES MELLITUS; ENZYME ACTIVITY; FIBRINOLYSIS; GENE CONTROL; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HEMOSTASIS; HUMAN; IMMUNE RESPONSE; INFLAMMATION; MALIGNANT NEOPLASTIC DISEASE; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN FAMILY; REVIEW; SIGNAL TRANSDUCTION; THROMBOSIS; TRANSCRIPTION REGULATION;

BLOOD COAGULATION; CYTOKINES; FIBRINOLYSIS; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; PLASMINOGEN ACTIVATORS; RNA PROCESSING, POST-TRANSCRIPTIONAL; TRANSCRIPTION, GENETIC;

EID: 34250692681     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02464.x     Document Type: Review

References (159)

1. Cesarman-Maus G, Hajjar KA. Molecular mechanisms of fibrinolysis. Br J Haematol 2005; 129: 307-21.
2. Ragno P. The urokinase receptor: A ligand or a receptor? Story of a sociable molecule. Cell Mol Life Sci 2006; 63: 1028-37.
3. Levi M, van der Poll T. Two-way interactions between inflammation and coagulation. Trends Cardiovasc Med 2005; 15: 254-9.
4. Bertina RM, van Tilburg NH, de Fouw NJ, Haverkate F. Thrombin, a link between coagulation activation and fibrinolysis. Ann N Y Acad Sci 1992; 667: 239-48.
5. Bouma BN, Mosnier LO. Thrombin activatable fibrinolysis inhibitor (TAFI) at the interface between coagulation and fibrinolysis. Pathophysiol Haemost Thromb 2003; 33: 375-81.
6. Esmon CT. The interactions between inflammation and coagulation. Br J Haematol 2005; 131: 417-30.
7. Bajzar L. Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway. Arterioscler Thromb Vasc Biol 2000; 20: 2511-8.
8. Myles T, Nishimura T, Yun TH, Nagashima M, Morser J, Patterson AJ, Pearl RG, Leung LL. Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. J Biol Chem 2003; 278: 51059-67.
9. Campbell W, Okada N, Okada H. Carboxypeptidase R is an inactivator of complement-derived inflammatory peptides and an inhibitor of fibrinolysis. Immunol Rev 2001; 180: 162-7.
10. Robson SC, Saunders R, Kirsch RE. Monocyte-macrophage release of IL-1 is inhibited by type-1 plasminogen activator inhibitors. J Clin Lab Immunol 1990; 33: 83-90.
11. Szaba FM, Smiley ST. Roles for thrombin and fibrin(ogen) in cytokine/ chemokine production and macrophage adhesion in vivo. Blood 2002; 99: 1053-9.
12. Massignon D, Lepape A, Bienvenu J, Barbier Y, Boileau C, Coeur P. Coagulation/fibrinolysis balance in septic shock related to cytokines and clinical state. Haemostasis 1994; 24: 36-48.
13. Agirbasli M, Inanc N, Baykan OA, Direskeneli H. The effects of TNF alpha inhibition on plasma fibrinolytic balance in patients with chronic inflammatory rheumatical disorders. Clin Exp Rheumatol 2006; 24: 580-3.
14. Mavri A, Bastelica D, Poggi M, Morange P, Peiretti F, Verdier M, Juhan-Vague I, Alessi MC. Polymorphism A36 G of the tumor necrosis factor receptor 1 gene is associated with PAI-1 levels in obese women. Thromb Haemost 2007; 97: 62-6.
15. Eriksson P, Kallin B, van't Hooft FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A 1995; 92: 1851-5.
16. Ladenvall P, Johansson L, Jansson JH, Jern S, Nilsson TK, Tjarnlund A, Jern C, Boman K. Tissue-type plasminogen activator -7,351C/T enhancer polymorphism is associated with a first myocardial infarction. Thromb Haemost 2002; 87: 105-9.
17. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.
18. Ross J. mRNA stability in mammalian cells. Microbiol Rev 1995; 59: 423-50.
19. Shaw G, Kamen R. A conserved AU sequence from the 3' untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell 1986; 46: 659-67.
20. Lagnado CA, Brown CY, Goodall GJ. AUUUA is not sufficient to promote poly(A) shortening and degradation of an mRNA: The functional sequence within AU-rich elements may be UUAUUUA(U/A)(U/A). Mol Cell Biol 1994; 14: 7984-95.
21. Couttet P, Fromont-Racine M, Steel D, Pictet R, Grange T. Messenger RNA deadenylylation precedes decapping in mammalian cells. Proc Natl Acad Sci U S A 1997; 94: 5628-33.
22. Decker CJ, Parker R. A turnover pathway for both stable and unstable mRNAs in yeast: Evidence for a requirement for deadenylation. Genes Dev 1993; 7: 1632-43.
23. Juhan-Vague I, Alessi MC. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost 1997; 78: 656-60.
24. Juhan-Vague I, Pyke SD, Alessi MC, Jespersen J, Haverkate F, Thompson SG. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation 1996; 94: 2057-63.
25. Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 1997; 46: 860-7.
26. Pandey M, Loskutoff DJ, Samad F. Molecular mechanisms of tumor necrosis factor-alpha-mediated plasminogen activator inhibitor-1 expression in adipocytes. FASEB J 2005; 19: 1317-9.
27. Nagamine Y, Medcalf RL, Munoz-Canoves P. Transcriptional and posttranscriptional regulation of the plasminogen activator system. Thromb Haemost 2005; 93: 661-75.
28. Kastl SP, Speidl WS, Kaun C, Rega G, Assadian A, Weiss TW, Valent P, Hagmueller GW, Maurer G, Huber K, Wojta J. The complement component C5a induces the expression of plasminogen activator inhibitor-1 in human macrophages via NF-kappaB activation. J Thromb Haemost 2006; 4: 1790-7.
29. Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier JM. Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J 1998; 17: 3091-100.
30. Woodward RN, Finn AV, Dichek DA. Identification of intracellular pathways through which TGF-beta1 upregulates PAI-1 expression in endothelial cells. Atherosclerosis 2006; 186: 92-100.
31. Chen YQ, Su M, Walia RR, Hao Q, Covington JW, Vaughan DE. Sp1 sites mediate activation of the plasminogen activator inhibitor-1 promoter by glucose in vascular smooth muscle cells. J Biol Chem 1998; 273: 8225-31.
32. Motojima M, Ando T, Yoshioka T. Sp1-like activity mediates angiotensin-II-induced plasminogen-activator inhibitor type-1 (PAI-1) gene expression in mesangial cells. Biochem J 2000; 349: 435-41.
33. Arts J, Grimbergen J, Toet K, Kooistra T. On the role of c-Jun in the induction of PAI-1 gene expression by phorbol ester, serum, and IL-1alpha in HepG2 cells. Arterioscler Thromb Vasc Biol 1999; 19: 39-46.
34. Knudsen H, Olesen T, Riccio A, Ungaro P, Christensen L, Andreasen PA. A common response element mediates differential effects of phorbol esters and forskolin on type-1 plasminogen activator inhibitor gene expression in human breast carcinoma cells. Eur J Biochem 1994; 220: 63-74.
35. Fink T, Kazlauskas A, Poellinger L, Ebbesen P, Zachar V. Identification of a tightly regulated hypoxia-response element in the promoter of human plasminogen activator inhibitor-1. Blood 2002; 99: 2077-83.
36. Gruber F, Hufnagl P, Hofer-Warbinek R, Schmid JA, Breuss JM, Huber-Beckmann R, Lucerna M, Papac N, Harant H, Lindley I, de Martin R, Binder BR. Direct binding of Nur77/NAK-1 to the plasminogen activator inhibitor 1 (PAI-1) promoter regulates TNF alpha-induced PAI-1 expression. Blood 2003; 101: 3042-8.
37. Hou B, Eren M, Painter CA, Covington JW, Dixon JD, Schoenhard JA, Vaughan DE. Tumor necrosis factor alpha activates the human plasminogen activator inhibitor-1 gene through a distal nuclear factor kappaB site. J Biol Chem 2004; 279: 18127-36.
38. Venugopal J, Hanashiro K, Nagamine Y. Regulation of PAI-1 gene expression during adipogenesis. J Cell Biochem 2007 [Epub ahead of print] DOI: 10.1002/jcb.21173.
39. Vergouwen MD, Frijns CJ, Roos YB, Rinkel GJ, Baas F, Vermeulen M. Plasminogen activator inhibitor-1 4 G allele in the 4 G/5 G promoter polymorphism increases the occurrence of cerebral ischemia after aneurysmal subarachnoid hemorrhage. Stroke 2004; 35: 1280-3.
40. Hoffstedt J, Andersson IL, Persson L, Isaksson B, Arner P. The common-675 4 G/5 G polymorphism in the plasminogen activator inhibitor-1 gene is strongly associated with obesity. Diabetologia 2002; 45: 584-7.
41. Nordt TK, Eschenfelder E, Peter K, Sobel BE, Bode C. Independence of growth factor induced plasminogen activator inhibitor type-1 (PAI-1) expression from the 4 G/5/G polymorphism of the PAI-1 gene. Thromb Haemost 2003; 90: 36-42.
42. Bosma PJ, Kooistra T. Different induction of two plasminogen activator inhibitor 1 mRNA species by phorbol ester in human hepatoma cells. J Biol Chem 1991; 266: 17845-9.
43. Fattal PG, Schneider DJ, Sobel BE, Billadello JJ. Post-transcriptional regulation of expression of plasminogen activator inhibitor type 1 mRNA by insulin and insulin-like growth factor 1. J Biol Chem 1992; 267: 12412-5.
44. Hopkins WE, Westerhausen DR Jr, Sobel BE, Billadello JJ. Transcriptional regulation of plasminogen activator inhibitor type-1 mRNA in Hep G2 cells by epidermal growth factor. Nucleic Acids Res 1991; 19: 163-8.
45. Bosma PJ, van den Berg EA, Kooistra T, Siemieniak DR, Slightom JL. Human plasminogen activator inhibitor-1 gene. Promoter and structural gene nucleotide sequences. J Biol Chem 1988; 263: 9129-41.
46. Ny T, Sawdey M, Lawrence D, Millan JL, Loskutoff DJ. Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor. Proc Natl Acad Sci U S A 1986; 83: 6776-80.
47. Westerhausen DR Jr, Hopkins WE, Billadello JJ. Multiple transforming growth factor-beta-inducible elements regulate expression of the plasminogen activator inhibitor type-1 gene in Hep G2 cells. J Biol Chem 1991; 266: 1092-100.
48. Heaton JH, Kathju S, Gelehrter TD. Transcriptional and posttranscriptional regulation of type 1 plasminogen activator inhibitor and tissue-type plasminogen activator gene expression in HTC rat hepatoma cells by glucocorticoids and cyclic nucleotides. Mol Endocrinol 1992; 6: 53-60.
49. Heaton JH, Tillmann-Bogush M, Leff NS, Gelehrter TD. Cyclic nucleotide regulation of type-1 plasminogen activator-inhibitor mRNA stability in rat hepatoma cells. Identification of cis-acting sequences. J Biol Chem 1998; 273: 14261-8.
50. Tillmann-Bogush M, Heaton JH, Gelehrter TD. Cyclic nucleotide regulation of PAI-1 mRNA stability. Identification of cytosolic proteins that interact with an a-rich sequence. J Biol Chem 1999; 274: 1172-9.
51. Bachmann F. The enigma PAI-2. Gene expression, evolutionary and functional aspects. Thromb Haemost 1995; 74: 172-9.
52. Kruithof EK, Baker MS, Bunn CL. Biological and clinical aspects of plasminogen activator inhibitor type 2. Blood 1995; 86: 4007-24.
53. Darnell GA, Antalis TM, Johnstone RW, Stringer BW, Ogbourne SM, Harrich D, Suhrbier A. Inhibition of retinoblastoma protein degradation by interaction with the serpin plasminogen activator inhibitor 2 via a novel consensus motif. Mol Cell Biol 2003; 23: 6520-32.
54. Kasyapa CS, Kunapuli P, Hawthorn L, Cowell JK. Induction of the plasminogen activator inhibitor-2 in cells expressing the ZNF198/FGFR1 fusion kinase that is involved in atypical myeloproliferative disease. Blood 2006; 107: 3693-9.
55. Yu H, Maurer F, Medcalf RL. Plasminogen activator inhibitor type 2: A regulator of monocyte proliferation and differentiation. Blood 2002; 99: 2810-8.
56. Macaluso M, Montanari M, Marshall CM, Gambone AJ, Tosi GM, Giordano A, Massaro-Giordano M. Cytoplasmic and nuclear interaction between Rb family proteins and PAI-2: A physiological crosstalk in human corneal and conjunctival epithelial cells. Cell Death Differ 2006; 13: 1515-22.
57. Park JM, Greten FR, Wong A, Westrick RJ, Arthur JS, Otsu K, Hoffmann A, Montminy M, Karin M. Signaling pathways and genes that inhibit pathogen-induced macrophage apoptosis-CREB and NF-kappaB as key regulators. Immunity 2005; 23: 319-9.
58. Kumar S, Baglioni C. Protection from tumor necrosis factor-mediated cytolysis by overexpression of plasminogen activator inhibitor type-2. J Biol Chem 1991; 266: 20960-4.
59. Dickinson JL, Bates EJ, Ferrante A, Antalis TM. Plasminogen activator inhibitor type 2 inhibits tumor necrosis factor alpha-induced apoptosis. Evidence for an alternate biological function. J Biol Chem 1995; 270: 27894-904.
60. Zhou HM, Bolon I, Nichols A, Wohlwend A, Vassalli JD. Overexpression of plasminogen activator inhibitor type 2 in basal keratinocytes enhances papilloma formation in transgenic mice. Cancer Res 2001; 61: 970-6.
61. Ritchie H, Fragoyannis A. Thrombin inhibits apoptosis of monocytes and plasminogen activator inhibitor 2 (PAI-2) is not responsible for this inhibition. Exp Cell Res 2000; 260: 20-9.
62. Medcalf RL, Kruithof EK, Schleuning WD. Plasminogen activator inhibitor 1 and 2 are tumor necrosis factor/cachectin-responsive genes. J Exp Med 1988; 168: 751-9.
63. Medcalf RL. Cell- and gene-specific interactions between signal transduction pathways revealed by okadaic acid. Studies on the plasminogen activating system. J Biol Chem 1992; 267: 12220-6.
64. Suzuki T, Hashimoto S, Toyoda N, Nagai S, Yamazaki N, Dong HY, Sakai J, Yamashita T, Nukiwa T, Matsushima K. Comprehensive gene expression profile of LPS-stimulated human monocytes by SAGE. Blood 2000; 96: 2584-91.
65. Buechler C, Ullrich H, Ritter M, Porsch-Oezcueruemez M, Lackner KJ, Barlage S, Friedrich SO, Kostner GM, Schmitz G. Lipoprotein (a) up-regulates the expression of the plasminogen activator inhibitor 2 in human blood monocytes. Blood 2001; 97: 981-6.
66. Medcalf RL, Stasinopoulos SJ. The undecided serpin. The ins and outs of plasminogen activator inhibitor type 2. FEBS J 2005; 272: 4858-67.
67. Cousin E, Medcalf RL, Bergonzelli GE, Kruithof EK. Regulatory elements involved in constitutive and phorbol ester-inducible expression of the plasminogen activator inhibitor type 2 gene promoter. Nucleic Acids Res 1991; 19: 3881-6.
68. Dear AE, Shen Y, Ruegg M, Medcalf RL. Molecular mechanisms governing tumor-necrosis-factor-mediated regulation of plasminogen-activator inhibitor type-2 gene expression. Eur J Biochem 1996; 241: 93-100.
69. Antalis TM, Costelloe E, Muddiman J, Ogbourne S, Donnan K. Regulation of the plasminogen activator inhibitor type-2 gene in monocytes: localization of an upstream transcriptional silencer. Blood 1996; 88: 3686-97.
70. Maurer F, Medcalf RL. Plasminogen activator inhibitor type 2 gene induction by tumor necrosis factor and phorbol ester involves transcriptional and post-transcriptional events. Identification of a functional nonameric AU-rich motif in the 3'-untranslated region. J Biol Chem 1996; 271: 26074-80.
71. Pytel BA, Peppel K, Baglioni C. Plasminogen activator inhibitor type-2 is a major protein induced in human fibroblasts and SK-MEL-109 melanoma cells by tumor necrosis factor. J Cell Physiol 1990; 144: 416-22.
72. Schleuning WD, Medcalf RL, Hession C, Rothenbuhler R, Shaw A, Kruithof EK. Plasminogen activator inhibitor 2: Regulation of gene transcription during phorbol ester-mediated differentiation of U-937 human histiocytic lymphoma cells. Mol Cell Biol 1987; 7: 4564-7.
73. Maurer F, Tierney M, Medcalf RL. An AU-rich sequence in the 3'-UTR of plasminogen activator inhibitor type 2 (PAI-2) mRNA promotes PAI-2 mRNA decay and provides a binding site for nuclear HuR. Nucleic Acids Res 1999; 27: 1664-73.
74. Yu H, Stasinopoulos S, Leedman P, Medcalf RL. Inherent instability of plasminogen activator inhibitor type 2 mRNA is regulated by tristetraprolin. J Biol Chem 2003; 278: 13912-8.
75. Carballo E, Lai WS, Blackshear PJ. Feedback inhibition of macrophage tumor necrosis factor-alpha production by tristetraprolin. Science 1998; 281: 1001-5.
76. Sitrin RG, Shollenberger SB, Strieter RM, Gyetko MR. Endogenously produced urokinase amplifies tumor necrosis factor-alpha secretion by THP-1 mononuclear phagocytes. J Leukoc Biol 1996; 59: 302-11.
77. Shushakova N, Eden G, Dangers M, Zwirner J, Menne J, Gueler F, Luft FC, Haller H, Dumler I. The urokinase/urokinase receptor system mediates the IgG immune complex-induced inflammation in lung. J Immunol 2005; 175: 4060-8.
78. Wu SQ, Aird WC. Thrombin, TNF-alpha, and LPS exert overlapping but nonidentical effects on gene expression in endothelial cells and vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2005; 289: H873-85.
79. Feliciani C, Toto P, Wang B, Sauder DN, Amerio P, Tulli A. Urokinase plasminogen activator mRNA is induced by IL-1alpha and TNF-alpha in in vitro acantholysis. Exp Dermatol 2003; 12: 466-71.
80. Moriwaki H, Stempien-Otero A, Kremen M, Cozen AE, Dichek DA. Overexpression of urokinase by macrophages or deficiency of plasminogen activator inhibitor type 1 causes cardiac fibrosis in mice. Circ Res 2004; 95: 637-44.
81. Stempien-Otero A, Plawman A, Meznarich J, Dyamenahalli T, Otsuka G, Dichek DA. Mechanisms of cardiac fibrosis induced by urokinase plasminogen activator. J Biol Chem 2006; 281: 15345-51.
82. Cozen AE, Moriwaki H, Kremen M, DeYoung MB, Dichek HL, Slezicki KI, Young SG, Veniant M, Dichek DA. Macrophage-targeted overexpression of urokinase causes accelerated atherosclerosis, coronary artery occlusions, and premature death. Circulation 2004; 109: 2129-35.
83. Falkenberg M, Tom C, DeYoung MB, Wen S, Linnemann R, Dichek DA. Increased expression of urokinase during atherosclerotic lesion development causes arterial constriction and lumen loss, and accelerates lesion growth. Proc Natl Acad Sci U S A 2002; 99: 10665-70.
84. Medcalf RL, Van den Berg E, Schleuning WD. Glucocorticoid-modulated gene expression of tissue- and urinary-type plasminogen activator and plasminogen activator inhibitor 1 and 2. J Cell Biol 1988; 106: 971-8.
85. Ziegler A, Knesel J, Fabbro D, Nagamine Y. Protein kinase C down-regulation enhances cAMP-mediated induction of urokinase-type plasminogen activator mRNA in LLC-PK1 cells. J Biol Chem 1991; 266: 21067-74.
86. Marksitzer R, Stief A, Menoud PA, Nagamine Y. Role of LFB3 in cell-specific cAMP induction of the urokinase-type plasminogen activator gene. J Biol Chem 1995; 270: 21833-8.
87. Verde P, Boast S, Franze A, Robbiati F, Blasi F. An upstream enhancer and a negative element in the 5' flanking region of the human urokinase plasminogen activator gene. Nucleic Acids Res 1988; 16: 10699-716.
88. D'Orazio D, Besser D, Marksitzer R, Kunz C, Hume DA, Kiefer B, Nagamine Y. Cooperation of two PEA3'AP1 sites in uPA gene induction by TPA and FGF-2. Gene 1997; 201: 179-87.
89. Rorth P, Nerlov C, Blasi F, Johnsen M. Transcription factor PEA3 participates in the induction of urokinase plasminogen activator transcription in murine keratinocytes stimulated with epidermal growth factor or phorbol-ester. Nucleic Acids Res 1990; 18: 5009-17.
90. Lee JS, von der Ahe D, Kiefer B, Nagamine Y. Cytoskeletal reorganization and TPA differently modify AP-1 to induce the urokinase-type plasminogen activator gene in LLC-PK1 cells. Nucleic Acids Res 1993; 21: 3365-72.
91. Besser D, Presta M, Nagamine Y. Elucidation of a signaling pathway induced by FGF-2 leading to uPA gene expression in NIH 3T3 fibroblasts. Cell Growth Differ 1995; 6: 1009-17.
92. Besser D, Bardelli A, Didichenko S, Thelen M, Comoglio PM, Ponzetto C, Nagamine Y. Regulation of the urokinase-type plasminogen activator gene by the oncogene Tpr-Met involves GRB2. Oncogene 1997; 14: 705-11.
93. Ried S, Jager C, Jeffers M, Vande Woude GF, Graeff H, Schmitt M, Lengyel E. Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factor. J Biol Chem 1999; 274: 16377-86.
94. Dunn SE, Torres JV, Oh JS, Cykert DM, Barrett JC. Up-regulation of urokinase-type plasminogen activator by insulin-like growth factor-I depends upon phosphatidylinositol-3 kinase and mitogen-activated protein kinase kinase. Cancer Res 2001; 61: 1367-74.
95. Lengyel E, Stepp E, Gum R, Boyd D. Involvement of a mitogen-activated protein kinase signaling pathway in the regulation of urokinase promoter activity by c-Ha-ras. J Biol Chem 1995; 270: 23007-12.
96. Gum R, Wang SW, Lengyel E, Yu D, Hung MC, Juarez J, Boyd D. Up-regulation of urokinase-type plasminogen activator expression by the HER2/neu proto-oncogene. Anticancer Res 1995; 15: 1167-72.
97. Hansen SK, Nerlov C, Zabel U, Verde P, Johnsen M, Baeuerle PA, Blasi F. A novel complex between the p65 subunit of NF-kappa B and c-Rel binds to a DNA element involved in the phorbol ester induction of the human urokinase gene. EMBO J 1992; 11: 205-13.
98. Nanbu R, Menoud PA, Nagamine Y. Multiple instability-regulating sites in the 3' untranslated region of the urokinase-type plasminogen activator mRNA. Mol Cell Biol 1994; 14: 4920-8.
99. Altus MS, Nagamine Y. Protein synthesis inhibition stabilizes urokinase-type plasminogen activator mRNA. Studies in vivo and in cell-free decay reactions. J Biol Chem 1991; 266: 21190-6.
100. Henderson BR, Tansey WP, Phillips SM, Ramshaw IA, Kefford RF. Transcriptional and posttranscriptional activation of urokinase plasminogen activator gene expression in metastatic tumor cells. Cancer Res 1992; 52: 2489-96.
101. Tran H, Schilling M, Wirbelauer C, Hess D, Nagamine Y. Facilitation of mRNA deadenylation and decay by the exosome-bound, DExH protein RHAU. Mol Cell 2004; 13: 101-11.
102. Estreicher A, Wohlwend A, Belin D, Schleuning WD, Vassalli JD. Characterization of the cellular binding site for the urokinase-type plasminogen activator. J Biol Chem 1989; 264: 1180-9.
103. Roldan AL, Cubellis MV, Masucci MT, Behrendt N, Lund LR, Dano K, Appella E, Blasi F. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J 1990; 9: 467-74.
104. Slot O, Brunner N, Locht H, Oxholm P, Stephens RW. Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: Increased concentrations in rheumatoid arthritis. Ann Rheum Dis 1999; 58: 488-92.
105. Xu Y, Berrou J, Chen X, Fouqueray B, Callard P, Sraer JD, Rondeau E. Induction of urokinase receptor expression in nephrotoxic nephritis. Exp Nephrol 2001; 9: 397-404.
106. Roelofs JJ, Rouschop KM, Teske GJ, Claessen N, Weening JJ, van der Poll T, Florquin S. The urokinase plasminogen activator receptor is crucially involved in host defense during acute pyelonephritis. Kidney Int 2006; 70: 1942-7.
107. Lund LR, Ronne E, Roldan AL, Behrendt N, Romer J, Blasi F, Dano K. Urokinase receptor mRNA level and gene transcription are strongly and rapidly increased by phorbol myristate acetate in human monocyte-like U937 cells. J Biol Chem 1991; 266: 5177-81.
108. Picone R, Kajtaniak EL, Nielsen LS, Behrendt N, Mastronicola MR, Cubellis MV, Stoppelli MP, Pedersen S, Dano K, Blasi F. Regulation of urokinase receptors in monocytelike U937 cells by phorbol ester phorbol myristate acetate. J Cell Biol 1989; 108: 693-702.
109. Makela TP, Alitalo R, Paulsson Y, Westermark B, Heldin CH, Alitalo K. Regulation of platelet-derived growth factor gene expression by transforming growth factor beta and phorbol ester in human leukemia cell lines. Mol Cell Biol 1987; 7: 3656-62.
110. Lund LR, Romer J, Ronne E, Ellis V, Blasi F, Dano K. Urokinase-receptor biosynthesis, mRNA level and gene transcription are increased by transforming growth factor beta 1 in human A549 lung carcinoma cells. EMBO J 1991; 10: 3399-407.
111. Soravia E, Grebe A, De Luca P, Helin K, Suh TT, Degen JL, Blasi F. A conserved TATA-less proximal promoter drives basal transcription from the urokinase-type plasminogen activator receptor gene. Blood 1995; 86: 624-35.
112. Allgayer H, Wang H, Wang Y, Heiss MM, Bauer R, Nyormoi O, Boyd D. Transactivation of the urokinase-type plasminogen activator receptor gene through a novel promoter motif bound with an activator protein-2 alpha-related factor. J Biol Chem 1999; 274: 4702-14.
113. Hapke S, Gawaz M, Dehne K, Kohler J, Marshall JF, Graeff H, Schmitt M, Reuning U, Lengyel E. beta(3)A-integrin downregulates the urokinase-type plasminogen activator receptor (u-PAR) through a PEA3/ets transcriptional silencing element in the u-PAR promoter. Mol Cell Biol 2001; 21: 2118-32.
114. Hapke S, Kessler H, Arroyo de Prada N, Benge A, Schmitt M, Lengyel E, Reuning U. Integrin alpha(v)beta(3)/vitronectin interaction affects expression of the urokinase system in human ovarian cancer cells. J Biol Chem 2001; 276: 26340-8.
115. Wang H, Yan C, Asangani I, Allgayer H, Boyd DD. Identification of an histone H3 acetylated/K4-methylated-bound intragenic enhancer regulatory for urokinase receptor expression. Oncogene 2006 [Epub ahead of print] DOI: 10.1038/sj.onc.121003.
116. Lund LR, Ellis V, Ronne E, Pyke C, Dano K. Transcriptional and post-transcriptional regulation of the receptor for urokinase-type plasminogen activator by cytokines and tumour promoters in the human lung carcinoma cell line A549. Biochem J 1995; 1: 345-52.
117. Shetty S, Muniyappa H, Halady PK, Idell S. Regulation of urokinase receptor expression by phosphoglycerate kinase. Am J Respir Cell Mol Biol 2004; 31: 100-6.
118. Shetty S, Kumar A, Idell S. Posttranscriptional regulation of urokinase receptor mRNA: Identification of a novel urokinase receptor mRNA binding protein in human mesothelioma cells. Mol Cell Biol 1997; 17: 1075-83.
119. Wang GJ, Collinge M, Blasi F, Pardi R, Bender JR. Posttranscriptional regulation of urokinase plasminogen activator receptor messenger RNA levels by leukocyte integrin engagement. Proc Natl Acad Sci U S A 1998; 95: 6296-301.
120. Tran H, Maurer F, Nagamine Y. Stabilization of urokinase and urokinase receptor mRNAs by HuR is linked to its cytoplasmic accumulation induced by activated mitogen-activated protein kinase-activated protein kinase 2. Mol Cell Biol 2003; 23: 7177-88.
121. Montuori N, Mattiello A, Mancini A, Santoli M, Taglialatela P, Caputi M, Rossi G, Ragno P. Urokinase-type plasminogen activator up-regulates the expression of its cellular receptor through a post-transcriptional mechanism. FEBS Lett 2001; 508: 379-84.
122. Levin EG, del Zoppo GJ. Localization of tissue plasminogen activator in the endothelium of a limited number of vessels. Am J Pathol 1994; 144: 855-61.
123. Chen CS, Lyons-Giordano B, Lazarus GS, Jensen PJ. Differential expression of plasminogen activators and their inhibitors in an organotypic skin coculture system. J Cell Sci 1993; 1: 45-53.
124. Teesalu T, Kulla A, Asser T, Koskiniemi M, Vaheri A. Tissue plasminogen activator as a key effector in neurobiology and neuropathology. Biochem Soc Trans 2002; 30: 183-9.
125. Renckens R, Roelofs JJ, Florquin S, de Vos AF, Pater JM, Lijnen HR, Carmeliet P, van't Veer C, van der Poll T. Endogenous tissue-type plasminogen activator is protective during Escherichia coli -induced abdominal sepsis in mice. J Immunol 2006;177: 1189-96.
126. Roelofs JJ, Rouschop KM, Leemans JC, Claessen N, de Boer AM, Frederiks WM, Lijnen HR, Weening JJ, Florquin S. Tissue-type plasminogen activator modulates inflammatory responses and renal function in ischemia reperfusion injury. J Am Soc Nephrol 2006; 17: 131-40.
127. Medcalf RL, Schleuning WD. Regulation of human tissue-type plasminogen activator gene transcription by epidermal growth factor and 3',5'-cyclic adenosine monophosphate. Mol Endocrinol 1991; 5: 1773-9.
128. Bulens F, Merchiers P, Ibanez-Tallon I, De Vriese A, Nelles L, Claessens F, Belayew A, Collen D. Identification of a multihormone responsive enhancer far upstream from the human tissue-type plasminogen activator gene. J Biol Chem 1997; 272: 663-71.
129. Medcalf RL, Van den Berg E, Schleuning WD. Glucocorticoid-modulated gene expression of tissue- and urinary-type plasminogen activator and plasminogen activator inhibitor 1 and 2. J Cell Biol 1988; 106: 971-8.
130. Tiberio A, Farina AR, Tacconelli A, Cappabianca L, Gulino A, Mackay AR. Retinoic acid-enhanced invasion through reconstituted basement membrane by human SK-N-SH neuroblastoma cells involves membrane-associated tissue-type plasminogen activator. Int J Cancer 1997; 73: 740-8.
131. Schleef RR, Bevilacqua MP, Sawdey M, Gimbrone MA Jr, Loskutoff DJ. Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. J Biol Chem 1988; 263: 5797-803.
132. Medcalf RL, Ruegg M, Schleuning WD. A DNA motif related to the cAMP-responsive element and an exon-located activator protein-2 binding site in the human tissue-type plasminogen activator gene promoter cooperate in basal expression and convey activation by phorbol ester and cAMP. J Biol Chem 1990; 265: 14618-26.
133. Costa M, Shen Y, Maurer F, Medcalf RL. Transcriptional regulation of the tissue-type plasminogen-activator gene in human endothelial cells: identification of nuclear factors that recognise functional elements in the tissue-type plasminogen-activator gene promoter. Eur J Biochem 1998; 258: 123-31.
134. Costa M, Medcalf RL. Differential binding of cAMP-responsive-element (CRE)-binding protein-1 and activating transcription factor-2 to a CRE-like element in the human tissue-type plasminogen activator (t-PA) gene promoter correlates with opposite regulation of t-PA by phorbol ester in HT-1080 and HeLa cells. Eur J Biochem 1996; 237: 532-8.
135. Arts J, Herr I, Lansink M, Angel P, Kooistra T. Cell-type specific DNA-protein interactions at the tissue-type plasminogen activator promoter in human endothelial and HeLa cells in vivo and in vitro. Nucleic Acids Res 1997; 25: 311-7.
136. Lux W, Klobeck HG, Daniel PB, Costa M, Medcalf RL, Schleuning WD. In vivo and in vitro analysis of the human tissue-type plasminogen activator gene promoter in neuroblastomal cell lines: Evidence for a functional upstream kappaB element. J Thromb Haemost 2005; 3: 1009-117.
137. Pecorino LT, Darrow AL, Strickland S. In vitro analysis of the tissue plasminogen activator promoter reveals a GC box-binding activity present in murine brain but undetectable in kidney and liver. Mol Cell Biol 1991; 11: 3139-47.
138. Ulfhammer E, Larsson P, Karlsson L, Hrafnkelsdottir T, Bokarewa M, Tarkowski A, Jern S. TNF-alpha mediated suppression of tissue type plasminogen activator expression in vascular endothelial cells is NF-kappaB- and p38 MAPK-dependent. J Thromb Haemost 2006; 4: 1781-9.
139. Wolf A, Medcalf RL, Jern C. The t-PA -7,351C > T enhancer polymorphism decreases Sp1 and Sp3 protein binding affinity and transcriptional responsiveness to retinoic acid. Blood 2005; 103: 1060-7.
140. Tjarnlund-Wolf A, Olsson L, Medcalf RL, Jern C. Regulation of endogenous tissue-type plasminogen activator expression is modulated by the -7351C > T enhancer polymorphism. J Thromb Haemost 2006; 4: 1414-8.
141. Ouyang Y, Huang P, Huang C. Influence of 5'-untranslated region (UTR) sequence on the regulation of human tissue plasminogen activator (t-PA) mRNA expression. Chin Sci Bull 1995; 40: 1378-83.
142. Henderson BR, Sleigh MJ. TATA box-independent transcription of the human tissue plasminogen activator gene initiates within a sequence conserved in related genes. FEBS Lett 1992; 309: 130-4.
143. Ouyang Y, Huang P, Huang C. Inhibitory effect of 3'-untranslated region (3'-UTR) of human tissue-plasminogen activator (ht-PA) mRNA on its expression. Sci China B 1995; 38: 1253-60.
144. Richter JD. Cytoplasmic polyadenylation in development and beyond. Microbiol Mol Biol Rev 1999; 63: 446-56.
145. Huarte J, Belin D, Vassalli A, Strickland S, Vassalli JD. Meiotic maturation of mouse oocytes triggers the translation and polyadenylation of dormant tissue-type plasminogen activator mRNA. Genes Dev 1987; 1: 1201-11.
146. Vassalli JD, Huarte J, Belin D, Gubler P, Vassalli A, O'Connell ML, Parton LA, Rickles RJ, Strickland S. Regulated polyadenylation controls mRNA translation during meiotic maturation of mouse oocytes. Genes Dev 1989; 3: 2163-71.
147. Huarte J, Stutz A, O'Connell ML, Gubler P, Belin D, Darrow AL, Strickland S, Vassalli JD. Transient translational silencing by reversible mRNA deadenylation. Cell 1992; 69: 1021-30.
148. Alizadeh Z, Kageyama S, Aoki F. Degradation of maternal mRNA in mouse embryos: Selective degradation of specific mRNAs after fertilization. Mol Reprod Dev 2005; 72: 281-90.
149. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14477-84.
150. Bajzar L, Nesheim ME, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood 1996; 88: 2093-100.
151. Sato T, Miwa T, Akatsu H, Matsukawa N, Obata K, Okada N, Campbell W, Okada H. Pro-carboxypeptidase R is an acute phase protein in the mouse, whereas carboxypeptidase N is not. J Immunol 2000; 165: 1053-8.
152. Zeerleder S, Schroeder V, Hack CE, Kohler HP, Wuillemin WA. TAFI and PAI-1 levels in human sepsis. Thromb Res 2006; 118: 205-12.
153. Boffa MB, Hamill JD, Maret D, Brown D, Scott ML, Nesheim ME, Koschinsky ML. Acute phase mediators modulate thrombin-activable fibrinolysis inhibitor (TAFI) gene expression in HepG2 cells. J Biol Chem 2003; 278: 9250-7.
154. Maret D, Boffa MB, Brien DF, Nesheim ME, Koschinsky ML. Role of mRNA transcript stability in modulation of expression of the gene encoding thrombin activable fibrinolysis inhibitor. J Thromb Haemost 2004; 2: 1969-79.
155. Hori Y, Nakatani K, Morioka K, Katsuki A, Gabazza EC, Yano Y, Nobori T, Adachi Y, Sumida Y. Insulin enhanced thrombin-activable fibrinolysis inhibitor expression through PI3 kinase/Akt pathway. Int J Mol Med 2005; 15: 265-8.
156. Boffa MB, Reid TS, Joo E, Nesheim ME, Koschinsky ML. Characterization of the gene encoding human TAFI (thrombin-activable fibrinolysis inhibitor; plasma procarboxypeptidase B). Biochemistry 1999; 38: 6547-58.
157. Franco RF, Fagundes MG, Meijers JC, Reitsma PH, Lourenco D, Morelli V, Maffei FH, Ferrari IC, Piccinato CE, Silva WA Jr, Zago MA. Identification of polymorphisms in the 5'-untranslated region of the TAFI gene: Relationship with plasma TAFI levels and risk of venous thrombosis. Haematologica 2001; 86: 510-7.
158. Henry M, Aubert H, Morange PE, Nanni I, Alessi MC, Tiret L, Juhan-Vague I. Identification of polymorphisms in the promoter and the 3' region of the TAFI gene: Evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood 2001; 97: 2053-8.
159. Boffa MB, Hamill JD, Bastajian N, Dillon R, Nesheim ME, Koschinsky ML. A role for CCAAT/enhancer-binding protein in hepatic expression of thrombin-activable fibrinolysis inhibitor. J Biol Chem 2002; 277: 25329-36.